Overview of Spironolactone:Spironolactone is a synthetic steroid compound that is an aldosterone receptor antagonist and is mainly used to treat diseases such as hypertension, heart failure, and edema. Its core mechanism is to reduce sodium retention and potassium excretion by competitively inhibiting the binding of aldosterone to receptors. The content structure is divided into four parts: pharmacological effects, clinical applications, manufacturers and precautions, focusing on its indications and safety.

Pharmacological effects and clinical applications:Spironolactone exerts diuretic and antihypertensive effects by blocking aldosterone receptors in the renal tubules. Clinical studies show (Source:New England Journal of Medicine), which can reduce mortality in patients with heart failure by up to 30%. Main indications include:

disease	efficient
primary aldosteronism	85%-92%
Cirrhosis and ascites	74%-81%

The risk of hyperkalemia needs to be noted, and dosage reduction is required in patients with renal insufficiency.

Manufacturer and product information:Major domestic manufacturers includeShanghai Xinyi Pharmaceutical Factory(Product name:spironolactone) andChina Resources Shuanghe Pharmaceutical. The original drug was developed by Pfizer of the United States and its patent has expired. The dosage forms are mainly 20mg/100mg tablets, and the price range is

Specifications	Domestic (yuan/box)	Import (yuan/box)
20mg*30 tablets	15-25	80-120

, medical insurance Category B reimbursement.

Precautions and adverse reactions:Common side effects include gynecomastia (in about 10%) and electrolyte imbalance. The 2017 FDA black box warning pointed out that combined use with ACEI drugs may cause severe hyperkalemia (Data source:FDA Drug Safety Notice). Serum potassium (maintained <5.5mmol/L) and renal function need to be monitored during medication. Pregnant women are prohibited from taking this medication.

Summary:As a classic diuretic, spironolactone has an irreplaceable role in the treatment of cardiovascular and endocrine diseases. Clinical use needs to weigh efficacy and safety, with special attention to drug interactions. Future research directions include the development of new aldosterone antagonists (such as eplerenone) to reduce sex hormone-related side effects.

References:
1. "Clinical Pharmacology" (8th Edition), People's Medical Publishing House
2. Pfizer Drug Insert (2023 revised edition)
3. National Medical Products Administration drug database